Castrate-resistant Prostate Cancer Market Size, Share and Growth Outlook, 2026

Castrate-resistant Prostate Cancer Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global Castrate-resistant Prostate Cancer Market size is forecast to increase from $12.81 Billion in 2026 to $24.97 Billion in 2034 at a CAGR of 8.7% between 2026 and 2034.

The Castrate-resistant Prostate Cancer market report provides detailed analysis and outlook of Castrate-resistant Prostate Cancer segments including By Application (Metastatic Castrate-Resistant Prostate Cancer, Non-Metastatic Castrate-Resistant Prostate Cancer ), By Biomarker & Research Application (Cell Culture Media & Reagents, Androgen Receptor, Tumor Cell Line Studies, Circulating Tumor Cell ), By End-Use Category (Pharmaceutical and Biotechnology Companies, Research Institutes, Clinical Laboratories) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Castrate-Resistant Prostate Cancer Industry Overview

Advancements in Precision Oncology Transforming mCRPC Treatment Strategies

The castrate-resistant prostate cancer industry continues to evolve through the integration of targeted therapies, biomarker-guided patient selection, and precision medicine approaches. As metastatic castrate-resistant prostate cancer remains one of the most challenging stages of prostate cancer management, pharmaceutical developers are focusing on novel treatment combinations designed to improve clinical outcomes beyond traditional androgen receptor-targeted therapies. Growing emphasis on personalized treatment strategies is driving innovation across chemotherapy combinations, radioligand therapies, molecular diagnostics, and targeted oncology platforms.

Phase 3 Clinical Development Expanding Therapeutic Opportunities

Clinical-stage pharmaceutical innovation remains a major driver within the castrate-resistant prostate cancer market. AB Science SA received authorization from both the U.S. Food and Drug Administration and the European Medicines Agency to initiate its confirmatory Phase 3 Study AB22007. The multicenter randomized trial is designed to evaluate the efficacy and safety of masitinib administered in combination with standard docetaxel and prednisone compared with docetaxel treatment alone in patients with metastatic castrate-resistant prostate cancer. The study represents an important step in assessing whether targeted kinase inhibition can enhance therapeutic outcomes when integrated into established chemotherapy regimens for advanced prostate cancer.

Biomarker-Based Patient Selection Strengthening Personalized Treatment Approaches

The industry is increasingly adopting biomarker-driven treatment strategies to optimize patient outcomes and improve therapeutic response rates. AB Science completed the validation of baseline alkaline phosphatase levels as a predictive patient selection biomarker for masitinib therapy. Historical findings from Study AB12003 demonstrated that patients with lower baseline alkaline phosphatase values of ≤250 IU/L and particularly ≤100 IU/L experienced progressively stronger clinical benefits when masitinib was introduced early in the disease course. The data showed a 47% reduction in disease progression risk, reflected by a hazard ratio of 0.53 and a statistically significant p-value of 0.002. These findings support the growing role of biomarker-guided treatment selection, particularly in patients with lower levels of metastatic bone involvement.

Precision Therapies Addressing Limitations of Traditional Treatment Sequencing

Treatment sequencing has become a central focus within advanced prostate cancer management due to the limited effectiveness of conventional androgen receptor-targeted agent switching strategies. Published clinical evidence indicates that sequential use of androgen receptor-targeted therapies often provides progression-free survival benefits of only three to five months in advanced castrate-resistant disease. As a result, clinical guidelines are increasingly emphasizing precision medicine alternatives. These include radioligand therapies such as Pluvicto ([177Lu]Lu-PSMA-617), which selectively targets prostate-specific membrane antigen-expressing cancer cells, as well as PARP inhibitor monotherapies for patients with confirmed BRCA gene mutations. The growing adoption of molecularly targeted treatment pathways is reshaping therapeutic decision-making across the castrate-resistant prostate cancer landscape.

Castrate-resistant Prostate Cancer Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Castrate-resistant Prostate Cancer market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Astellas Pharma Inc., Pfizer Inc., Janssen Pharmaceuticals (Johnson & Johnson), Bayer AG, AstraZeneca plc, Sanofi S.A., Novartis AG, Merck & Co., Inc., Bristol Myers Squibb Company, Takeda Pharmaceutical Company Limited. The Castrate-resistant Prostate Cancer market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Castrate-resistant Prostate Cancer industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth Castrate-resistant Prostate Cancer Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by Castrate-resistant Prostate Cancer companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional Castrate-resistant Prostate Cancer markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Castrate-resistant Prostate Cancer Market Competitive Benchmarking and Company Analysis

Leading companies in Castrate-resistant Prostate Cancer industry include- Astellas Pharma Inc., Pfizer Inc., Janssen Pharmaceuticals (Johnson & Johnson), Bayer AG, AstraZeneca plc, Sanofi S.A., Novartis AG, Merck & Co., Inc., Bristol Myers Squibb Company, Takeda Pharmaceutical Company Limited. The Castrate-resistant Prostate Cancer market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Castrate-resistant Prostate Cancer Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Castrate-resistant Prostate Cancer market remains one of the strongest-performing segments in the country.
The US Castrate-resistant Prostate Cancer Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Castrate-resistant Prostate Cancer market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Castrate-resistant Prostate Cancer industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Castrate-resistant Prostate Cancer markets

Canada's strong Castrate-resistant Prostate Cancer sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Castrate-resistant Prostate Cancer market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Castrate-resistant Prostate Cancer Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Castrate-resistant Prostate Cancer market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Castrate-resistant Prostate Cancer population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Castrate-resistant Prostate Cancer industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Castrate-resistant Prostate Cancer market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Castrate-resistant Prostate Cancer sales through 2034

France Castrate-resistant Prostate Cancer companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Castrate-resistant Prostate Cancer Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Castrate-resistant Prostate Cancer distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China Castrate-resistant Prostate Cancer Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Castrate-resistant Prostate Cancer market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Castrate-resistant Prostate Cancer industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Castrate-resistant Prostate Cancer industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Castrate-resistant Prostate Cancer Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Castrate-resistant Prostate Cancer market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Castrate-resistant Prostate Cancer market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Castrate-resistant Prostate Cancer Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Castrate-resistant Prostate Cancer Market Segmentation

By Application
Metastatic Castrate-Resistant Prostate Cancer
Non-Metastatic Castrate-Resistant Prostate Cancer
By Biomarker & Research Application
Cell Culture Media & Reagents
Androgen Receptor
Tumor Cell Line Studies
Circulating Tumor Cell
By End-Use Category
Pharmaceutical and Biotechnology Companies
Research Institutes
Clinical Laboratories

Top Companies in Castrate-resistant Prostate Cancer Industry

Astellas Pharma Inc.
Pfizer Inc.
Janssen Pharmaceuticals (Johnson & Johnson)
Bayer AG
AstraZeneca plc
Sanofi S.A.
Novartis AG
Merck & Co., Inc.
Bristol Myers Squibb Company
Takeda Pharmaceutical Company Limited

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

Latest Market Updates In Healthcare

Support this report with fresh, same-industry updates that strengthen topical depth and internal linking.

Market Update

Rise of Functional and Clinical-Grade Skincare

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025